Impact of food preservatives based on immobilized phenolic compounds on an in vitro model of human gut microbiota.

Bacteroidetes Covalent immobilization Eugenol Food preservatives Gut microbiota Natural antimicrobial

Journal

Food chemistry
ISSN: 1873-7072
Titre abrégé: Food Chem
Pays: England
ID NLM: 7702639

Informations de publication

Date de publication:
01 Mar 2023
Historique:
received: 13 01 2022
revised: 13 09 2022
accepted: 18 09 2022
pubmed: 29 9 2022
medline: 11 11 2022
entrez: 28 9 2022
Statut: ppublish

Résumé

To address concerns about the biocompatibility of novel phenolic immobilization-based food preservatives, their impact on the composition and metabonomic profile of a defined community of human gut microbiota was evaluated. Three phenolics (eugenol, vanillin and ferulic acid) presented in two forms (free or immobilized on different supports) were tested at two concentration levels (0.5 and 2 mg/mL). Free eugenol was the phenolic with the greatest impact on gut microbiota, with a remarkable increase in the abundance of Lachnospiraceae and Akkermansiaceae families. In contrast, immobilized phenolics produced an increase in the abundance of Bacteroides with a reduction in the ratio of Firmicutes to Bacteroidetes. The metabonomic profile was also affected by free and immobilized phenolics differently in terms of fermentation by-products and phenolic biotransformation metabolites. Thus the results suggest the importance of evaluating the impact of new compounds or materials added to food on human gut microbiota and their potential use to modulate microbiota composition.

Identifiants

pubmed: 36170787
pii: S0308-8146(22)02325-1
doi: 10.1016/j.foodchem.2022.134363
pii:
doi:

Substances chimiques

Food Preservatives 0
Eugenol 3T8H1794QW
Phenols 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

134363

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The author declare the following financial interests/personal relationships which may be considered as potential competing interests: Emma Allen-Vercoe is the CSO and co-founder of NuBiyota LLC, a company that is developing human gut microbiota-based live microbial products to treat a range of indications. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

María Ruiz-Rico (M)

Departamento de Tecnología de Alimentos, Universitat Politècnica de València, Valencia, Spain. Electronic address: maruiri@etsia.upv.es.

Simone Renwick (S)

Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.

Sarah J Vancuren (SJ)

Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.

Avery V Robinson (AV)

Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.

Connor Gianetto-Hill (C)

Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.

Emma Allen-Vercoe (E)

Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.

José M Barat (JM)

Departamento de Tecnología de Alimentos, Universitat Politècnica de València, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH